A PATIENTS WITH LOWER RESPIRATORY TRACT INFECTION. A CONSILIUM
https://doi.org/10.18093/0869-0189-2014-0-2-122-126
Abstract
In primary care, the most common lower respiratory tract infections are acute bronchitis, acute exacerbation of chronic bronchitis / chronic obstructive pulmonary disease (COPD) and community-acquired pneumonia. A general practitioner should make a decision about management of such patient considering clinical and laboratory data. Two cases of an acute exacerbation of COPD and community-acquired pneumonia were discussed in the article. Issues of optimal antibacterial therapy were reviewed. The main pathogens causing acute exacerbation of chronic bronchitis / COPD are S. pneumoniae, H. influenzae, M. catarrhalis, so preferable antibiotics in this case could be aminopenicillines, macrolides, newer fluoroquinolones. According to the results of PeGAS survey josamycin is a macrolide with the highest activity against S. pneumoniae.
About the Author
L. I. Dvoretsky
ГБОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России: 119991, Москва, ул. Трубецкая, 8, стр. 2
Russian Federation
Russian Federation
References
1. Raherison С., Peray Р., Poirier R. et al. Management of lower respiratory tract infections by French general practitioners: the AIR II study. Eur. Respir. J. 2002; 19: 314–319.
2. Anthonisen N.R., Manfreda J., Warren C.P. еt al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
3. Eller J., Ede A., Schaberg T. еt al. Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest. 1998; 113: 1542–1548.
4. Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. Результаты многоцентрового проспективного исследования ПеГАС. Клиническая микробиология и антимикробная химиотерапия. 2010; 12 (4): 329–341. / Kozlov R.S., Sivaya O.V., Krechikova O.I. et al. Changes in antibacterial resistance of Streptococcus pneumoniae in 1999–2009 in Russia. The results of the multicenter prospective survey PeGAS. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2010; 12 (4): 329–341 (in Russian).
5. Martinez F.J., Han M.K., Flaherty K., Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert. Rev. Antiinfect. Ther. 2006; 4 (1): 101–124.
6. Дворецкий Л.И. Инфекционное обострение хронической обструктивной болезни легких: от своевременной диагностики к адекватной антибактериальной терапии. Cправочник поликлинического врача. 2008; 9: 28–32. / Dvoretsky L.I. Infectious exacerbation of chronic obstructive pulmonary disease: from timely diagnosis to adequate antibacterial therapy. Cpravochnik Poliklinicheskogo Vracha. 2008; 9: 28–32 (in Russian).
7. WHO Model Prescribing Information, Drugs Used in Bacterial Infections. Geneva: WHO; 2001.
8. Garau J., Twynholm M., Garcia-Mendez E. et al. Oral pharmacokinetically enhanced co-amoxiclav 2000 / 125 mg, twice daily, compared with co-amoxiclav 875 / 125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J. Antimicrob. Chemother. 2003; 52: 826–836.
9. Henry D.C., Riffer E., Sokol W.N. et al. Randomized doubleblind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob. Agents Chemother. 2003; 47: 2770–2774.
10. File T.M. Jr, Lode H., Kurz H. et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000 / 125 milligrams) versus those of amoxicillin-clavulanate (875 / 125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2004; 48: 3323–3331.
11. Sourgens H., Steinbrede H., Verschoor J.S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator filmcoated tablet. Int. J. Clin. Pharmacol. Ther. 2001; 39: 75–82.
12. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование. Пульмонология. 2008; 2: 73–80. / Guchev I.A., Kozlov R.S. Safety and efficacy of different drug formulations of amoxicillin / clavulanate in lower respiratory infections in adults. Pul'monologiya. 2008; 2: 73–80 (in Russian).
13. Чучалин А.Г, Синопальников А.С., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. М.: РРО, МАКМАХ; 2010. / Chuchalin A.G., Sinopalnikov A.I., Kozlov R.S. et al. Community-Acquired Pneumonia in Adults: Practical Guidelines on Diagnosis, Treatment and Prevention. Handbook for physicians [Vnebol'nichnaya Pnevmoniya u Vzroslykh: Prakticheskie Rekomendatsii po Diagnostike, Lecheniyu i Profilaktike. Posobie dlya vrachey]. Moscow: RRO, MAKMAKh; 2010 (in Russian).
14. Страчунский Л.С., Козлов С.Н., ред. Джосамицин. Макролиды в современной клинической практике. Смоленск: Русич; 1998: 229–236. / Strachunskiy L.S., Kozlov S.N., eds. Josamycin. Macrolides in Recent Clinical Practice [Dzhosamitsin. Makrolidy v Sovremennoy Klinicheskoy Praktike]. Smolensk: Rusich; 1998: 229–236 (in Russian).
15. Fraschini F. Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis. J. Int. Med. Res. 1990; 18: 171–176.
16. Sefton A.M., Maskell J.P., Kerawala C.et al. Comparative efficacy and tolerance of erythromycin and josamycin in the prevention of bacteraemia following dental extraction. J. Antimicrob. Chemother. 1990; 25: 975–984.
17. Straneo G., Scarpazza G. Efficacy and safety of clarithromycin versus josamycin, in the treatment of hospitalized patients with bacterial pneumonia. J. Int. Med. Res.1990;18:64–170.
18. Белоусов Ю.Б., Синопальников А.И., Яковлев С.В. и др. Эффективность и безопасность джозамицина при лечении нетяжелой внебольничной пневмонии: результаты многоцентрового клинического исследования. Клиническая микробиология и антимикробная химиотерапия. 2007; 9 (1): 48–56. / Belousov Yu.B., Sinopalnikov A.I., Yakovlev S.V. et al. Efficacy and safety of Josamycin in therapy of non-severe community-acquired pneumonia: the results of multicenter clinical trial. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2007; 9 (1): 48–56 (in Russian).
19. Lozano R., Balaguer A. Josamycin in the treatment of bronchopulmonary infections. Clin. Ther. 1991; 13 (2): 281–288.
20. Карагодина Ю.Я., Захарова Н.К., Холод О.Л., Мичурина С.В. Безопасность и эффективность новой формы джозамицина при инфекциях дыхательных путей у взрослых: результаты проспективного наблюдательного исследования. Пульмонология. 2009; 5: 98–106. / Karagodina Yu.Ya., Zakharova N.K., Kholod O.L., Michurina S.V. Safety and efficacy of a new formulation of Josamycin in respiratory infections in adults. Pul'monologiya. 2009; 5: 98–106 (in Russian).
Review
For citations:
Dvoretsky L.I. A PATIENTS WITH LOWER RESPIRATORY TRACT INFECTION. A CONSILIUM. PULMONOLOGIYA. 2014;(2):122-126. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-2-122-126
Views:
2913
Email this article 